文献一覧: 太田満 (著者)

62 0 0 0 OA 和愛辞典 : 草稿版

著者: 太田満
出版者: 北海道大学アイヌ・先住民研究センター
巻号頁・発行日: pp.1-890, 2022-12-20

2024-01-06 18:03:54
62 + 129 Twitter

http://hdl.handle.net/2115/87707

3 0 0 0 OA <技術・研究報告>和歌山県沿岸で捕獲されたホクロヤッコとハナフエフキ

著者: 山本泰司加藤哲哉太田満荒賀忠一
出版者: 京都大学フィールド科学教育研究センター瀬戸臨海実験所
雑誌: 瀬戸臨海実験所年報 = Annual report of the Seto Marine Biological Laboratory (ISSN:09136002)
巻号頁・発行日: vol.21, pp.35-36, 2008-12-25

2016-07-24 11:40:08
3 + 1 Twitter

http://hdl.handle.net/2433/179073

1 0 0 0 OA 多民族学習としての小学校歴史学習アイヌ史の位置づけを中心に

著者: 太田満
出版者: 日本社会科教育学会
雑誌: 社会科教育研究 (ISSN:09158154)
巻号頁・発行日: vol.2012, no.117, pp.16-26, 2012 (Released:2016-12-01)

2024-01-11 11:45:15
1 + 1 Twitter

1 0 0 0 OA 司馬遼太郎『覇王の家』とその依拠史料

著者: 太田満明
雑誌: 兵庫教育大学近代文学雑志 (ISSN:09188770)
巻号頁・発行日: vol.9, pp.1-19, 1998-03

2022-05-05 13:27:00
1 + 0 Twitter

http://hdl.handle.net/10132/443

1 0 0 0 OA メチシリン耐性黄色ブドウ球菌感染患者における硫酸アルベカシンの血清中濃度モニタリングの有用性についての研究

著者: 祢宜田和正山下雅代久保田敏行杉浦洋二三浦崇則勝見章男太田満齋竹達郎戸澤良夫水谷勝
出版者: 一般社団法人日本医療薬学会
雑誌: 医療薬学 (ISSN:1346342X)
巻号頁・発行日: vol.27, no.2, pp.123-131, 2001-04-10 (Released:2011-03-04)
参考文献数: 17
被引用文献数: 1 2

Although vancomycin has been exclusively used for methicillin-resistant Staphylococcus aureus (MRSA) therapy, there are many patients recently observed to suffer from gram negative bacteria, Pseudomonas aeruginosa as well as MRSA.Arbekacin (ABK), an aminoglycoside antibiotic (AG) is an alternative medication for such patients with those infection disease. However, it seems that the dosage of ABK used according to the manufacture's recommendations is insufficient for MRSA therapy to obtain a sufficient patient outcomes. Moreover, the relationship between the effectiveness of ABK on MRSA infection and the serum ABK concentration remains unclear. For the long-term treatment of AG, we can not rule out the possibility that AG may induce nephrotoxicity and ototoxicity.Therefore, the present study was carried out to clarify the significance of therapeutic drug monitoring (TDM) of ABK for patients with an MRSA infection, and elucidate the relationship between the serum ABK level and its clinical outcomes, including its antibacterial action and side effects. We investigated 30 patients with an MRSA infection, who received ABK at the Anjo Kosei Hospital from September 1996 to June 1998. The treatment of the patients by ABK but without TDM showed a 46.6% (7/15) therapeutic efficacy, while the patients with drug monitoring had a remarkably successful therapeutic efficacy (100% : 21/21) with a peak serum ABK concentration over 10μg/mL. Dysphagia badly affected the efficacy of ABK therapy in patients with an MRSA infection even when the serum ABK level was well-controlled. The incidence of ABK induced nephrotoxicity was observed in all patients when ABK was administered at a total dose of over 5, 000mg, while it was 4% at a total dose of less than 5, 000mg. When the duration of ABK therapy was longer than 2 weeks, the incidence of nephrotoxicity also significantly increased.These results thus suggest that TDM of ABK is useful for increasing the efficacy of ABK therapy in patients with an MRSA infection. In light of nephrotoxicity, these results indicate that ABK therapy may be completed within 2 weeks with an ABK dose of less than 5, 000mg, as the total dose.